Altamira End Period Cash Flow vs Begin Period Cash Flow Analysis

CYTO Stock

USD 0.46 0.01 2.13%

Altamira Therapeutics financial indicator trend analysis is way more than just evaluating Altamira Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Altamira Therapeutics is a good investment. Please check the relationship between Altamira Therapeutics End Period Cash Flow and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.

End Period Cash Flow vs Begin Period Cash Flow

End Period Cash Flow vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Altamira Therapeutics End Period Cash Flow account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Altamira Therapeutics' End Period Cash Flow and Begin Period Cash Flow is 0.74. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Altamira Therapeutics, assuming nothing else is changed. The correlation between historical values of Altamira Therapeutics' End Period Cash Flow and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Altamira Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of End Period Cash Flow i.e., Altamira Therapeutics' End Period Cash Flow and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.74

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

End Period Cash Flow

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Altamira Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altamira Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.At this time, Altamira Therapeutics' Selling General Administrative is very stable compared to the past year. Tax Provision is expected to grow at the current pace this year, while Enterprise Value Over EBITDA is likely to drop (0.71).

Altamira Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Non Currrent Assets Other	Common Stock Shares Outstanding	Inventory	Short Long Term Debt Total
Total Assets		0.56	0.33	0.91	0.35	-0.95	-0.07	0.32	0.97	-0.08	0.97	0.74	0.6	0.23	0.32	-0.14	0.24	0.38	-0.11	0.98	-0.08	0.6	0.01	-0.26	0.12	0.29
Other Current Liab	0.56		0.57	0.25	0.43	-0.42	-0.38	0.18	0.57	-0.18	0.57	0.45	0.78	0.34	0.8	-0.09	0.37	0.79	-0.11	0.58	-0.18	0.78	0.26	-0.37	0.09	0.31
Total Current Liabilities	0.33	0.57		-0.05	0.56	-0.1	-0.37	0.48	0.33	-0.11	0.33	-0.02	0.38	0.34	0.42	-0.16	0.33	0.89	0.14	0.34	-0.11	0.38	0.02	-0.34	0.2	0.28
Total Stockholder Equity	0.91	0.25	-0.05		0.12	-0.95	0.11	0.16	0.88	-0.02	0.88	0.76	0.38	0.06	0.0	-0.08	0.1	-0.03	-0.13	0.88	-0.01	0.37	-0.05	-0.09	0.05	0.16
Property Plant And Equipment Net	0.35	0.43	0.56	0.12		-0.12	-0.54	0.8	0.22	0.4	0.22	-0.06	0.21	0.23	0.41	-0.18	0.54	0.59	0.62	0.26	0.38	0.21	-0.48	-0.2	0.26	0.02
Net Debt	-0.95	-0.42	-0.1	-0.95	-0.12		-0.12	-0.17	-0.97	0.26	-0.97	-0.84	-0.58	-0.2	-0.16	0.13	-0.06	-0.15	0.26	-0.96	0.25	-0.58	-0.18	0.24	-0.13	-0.38
Retained Earnings	-0.07	-0.38	-0.37	0.11	-0.54	-0.12		-0.65	0.07	-0.57	0.07	-0.01	0.09	-0.39	-0.3	-0.26	-0.97	-0.4	-0.24	0.05	-0.6	0.08	0.37	0.36	0.35	0.45
Accounts Payable	0.32	0.18	0.48	0.16	0.8	-0.17	-0.65		0.21	0.35	0.21	0.06	-0.03	0.29	0.15	-0.1	0.69	0.4	0.53	0.23	0.34	-0.02	-0.4	-0.25	0.15	-0.12
Cash	0.97	0.57	0.33	0.88	0.22	-0.97	0.07	0.21		-0.31	1.0	0.78	0.69	0.26	0.34	-0.17	0.09	0.39	-0.25	1.0	-0.31	0.69	0.22	-0.3	0.18	0.46
Non Current Assets Total	-0.08	-0.18	-0.11	-0.02	0.4	0.26	-0.57	0.35	-0.31		-0.31	-0.31	-0.53	-0.12	-0.17	0.19	0.61	-0.16	0.55	-0.29	0.99	-0.53	-0.87	0.2	-0.31	-0.79
Cash And Short Term Investments	0.97	0.57	0.33	0.88	0.22	-0.97	0.07	0.21	1.0	-0.31		0.78	0.69	0.26	0.34	-0.17	0.09	0.39	-0.25	1.0	-0.31	0.69	0.22	-0.3	0.18	0.46
Net Receivables	0.74	0.45	-0.02	0.76	-0.06	-0.84	-0.01	0.06	0.78	-0.31	0.78		0.57	0.25	0.16	0.2	0.15	0.07	-0.42	0.78	-0.29	0.57	0.45	-0.3	-0.13	0.24
Common Stock Total Equity	0.6	0.78	0.38	0.38	0.21	-0.58	0.09	-0.03	0.69	-0.53	0.69	0.57		0.33	0.71	-0.17	-0.08	0.61	-0.35	0.69	-0.52	1.0	0.48	-0.39	0.24	0.66
Short Term Investments	0.23	0.34	0.34	0.06	0.23	-0.2	-0.39	0.29	0.26	-0.12	0.26	0.25	0.33		0.2	0.1	0.39	0.33	-0.5	0.26	-0.06	0.33	0.12	-0.95	-0.13	0.46
Non Current Liabilities Total	0.32	0.8	0.42	0.0	0.41	-0.16	-0.3	0.15	0.34	-0.17	0.34	0.16	0.71	0.2		-0.1	0.24	0.79	-0.04	0.34	-0.18	0.71	0.26	-0.23	0.13	0.24
Other Current Assets	-0.14	-0.09	-0.16	-0.08	-0.18	0.13	-0.26	-0.1	-0.17	0.19	-0.17	0.2	-0.17	0.1	-0.1		0.25	-0.16	-0.2	-0.17	0.22	-0.17	0.19	-0.1	-0.94	-0.31
Other Stockholder Equity	0.24	0.37	0.33	0.1	0.54	-0.06	-0.97	0.69	0.09	0.61	0.09	0.15	-0.08	0.39	0.24	0.25		0.34	0.22	0.11	0.64	-0.07	-0.42	-0.36	-0.36	-0.46
Total Liab	0.38	0.79	0.89	-0.03	0.59	-0.15	-0.4	0.4	0.39	-0.16	0.39	0.07	0.61	0.33	0.79	-0.16	0.34		0.08	0.4	-0.16	0.61	0.14	-0.35	0.2	0.31
Property Plant And Equipment Gross	-0.11	-0.11	0.14	-0.13	0.62	0.26	-0.24	0.53	-0.25	0.55	-0.25	-0.42	-0.35	-0.5	-0.04	-0.2	0.22	0.08		-0.23	0.48	-0.35	-0.6	0.58	0.27	-0.47
Total Current Assets	0.98	0.58	0.34	0.88	0.26	-0.96	0.05	0.23	1.0	-0.29	1.0	0.78	0.69	0.26	0.34	-0.17	0.11	0.4	-0.23		-0.28	0.69	0.2	-0.3	0.18	0.45
Intangible Assets	-0.08	-0.18	-0.11	-0.01	0.38	0.25	-0.6	0.34	-0.31	0.99	-0.31	-0.29	-0.52	-0.06	-0.18	0.22	0.64	-0.16	0.48	-0.28		-0.52	-0.87	0.12	-0.35	-0.77
Common Stock	0.6	0.78	0.38	0.37	0.21	-0.58	0.08	-0.02	0.69	-0.53	0.69	0.57	1.0	0.33	0.71	-0.17	-0.07	0.61	-0.35	0.69	-0.52		0.48	-0.39	0.24	0.66
Non Currrent Assets Other	0.01	0.26	0.02	-0.05	-0.48	-0.18	0.37	-0.4	0.22	-0.87	0.22	0.45	0.48	0.12	0.26	0.19	-0.42	0.14	-0.6	0.2	-0.87	0.48		-0.17	-0.04	0.53
Common Stock Shares Outstanding	-0.26	-0.37	-0.34	-0.09	-0.2	0.24	0.36	-0.25	-0.3	0.2	-0.3	-0.3	-0.39	-0.95	-0.23	-0.1	-0.36	-0.35	0.58	-0.3	0.12	-0.39	-0.17		0.13	-0.53
Inventory	0.12	0.09	0.2	0.05	0.26	-0.13	0.35	0.15	0.18	-0.31	0.18	-0.13	0.24	-0.13	0.13	-0.94	-0.36	0.2	0.27	0.18	-0.35	0.24	-0.04	0.13		0.41
Short Long Term Debt Total	0.29	0.31	0.28	0.16	0.02	-0.38	0.45	-0.12	0.46	-0.79	0.46	0.24	0.66	0.46	0.24	-0.31	-0.46	0.31	-0.47	0.45	-0.77	0.66	0.53	-0.53	0.41

Click cells to compare fundamentals

Altamira Therapeutics Account Relationship Matchups

Altamira Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.2M	20.8M	18.8M	6.3M	7.7M	7.3M
Other Current Liab	1.3M	1.8M	1.2M	2.1M	376.1K	357.3K
Total Current Liabilities	2.3M	3.0M	4.9M	12.9M	888.9K	844.5K
Total Stockholder Equity	6.0M	16.8M	12.7M	(8.3M)	6.5M	9.6M
Property Plant And Equipment Net	66.7K	46.6K	564.7K	445.8K	80.1K	76.1K
Net Debt	(1.4M)	(10.7M)	(408.5K)	6.3M	(517.8K)	(543.6K)
Retained Earnings	(152.8M)	(160.6M)	(176.0M)	(201.4M)	(18.0M)	(18.9M)
Accounts Payable	938.2K	722.3K	3.5M	4.8M	413.1K	392.5K
Cash	1.4M	11.3M	984.2K	15.4K	617.4K	586.5K
Non Current Assets Total	6.9M	9.2M	15.1M	4.5M	6.5M	4.7M
Cash And Short Term Investments	1.4M	11.3M	984.2K	15.4K	617.4K	586.5K
Net Receivables	335.3K	80.9K	21.7K	6.5K	74.8K	71.1K
Common Stock Total Equity	19.3M	710.3K	1.7M	114.2K	102.8K	97.6K
Liabilities And Stockholders Equity	9.2M	20.8M	18.8M	6.3M	7.7M	7.3M
Non Current Liabilities Total	911.9K	999.6K	1.3M	1.7M	346.6K	329.3K
Other Current Assets	989.1M	288.1K	2.2M	979.4K	530.9K	504.4K
Other Stockholder Equity	157.2M	177.2M	188.8M	192.8M	24.3M	23.1M
Total Liab	3.2M	4.0M	6.1M	14.6M	1.2M	1.2M
Property Plant And Equipment Gross	33.9K	66.7K	46.6K	1.2M	935.2K	982.0K
Total Current Assets	2.4M	11.6M	3.8M	1.8M	1.2M	1.2M
Accumulated Other Comprehensive Income	(27.6K)	61.3K	62.1K	258.0K	177.6K	186.5K
Intangible Assets	6.8M	9.1M	14.3M	3.9M	4.5M	4.2M
Common Stock	1.7M	114.2K	149.6K	236.0K	2.6K	2.5K
Non Currrent Assets Other	20.0K	(9.2M)	(15.1M)	(4.5M)	(4.1M)	(4.3M)
Common Stock Shares Outstanding	14.5K	15.0K	33.1K	45.5K	491.3K	515.8K
Inventory	(988.5M)	(358.2M)	839.2K	11.6K	(74.8K)	(78.6K)
Other Liab	1.7M	911.9K	999.6K	812.0K	730.8K	1.3M
Net Tangible Assets	114.4K	(729.5K)	7.7M	(1.6M)	(1.9M)	(1.8M)
Net Invested Capital	6.0M	17.3M	12.7M	(2.4M)	6.5M	6.1M
Net Working Capital	95.8K	8.6M	(1.1M)	(11.1M)	334.2K	428.6K
Property Plant Equipment	33.9K	66.7K	46.6K	564.7K	649.4K	681.9K
Capital Stock	1.7M	114.2K	149.6K	236.0K	2.6K	2.5K

Pair Trading with Altamira Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Altamira Stock

0.8	VALN	Valneva SE ADR	Pair Corr
0.76	ERNA	Eterna Therapeutics	Pair Corr

Moving against Altamira Stock

0.87	BMY	Bristol Myers Squibb	Pair Corr
0.84	GILD	Gilead Sciences	Pair Corr
0.62	ESPR	Esperion Therapeutics	Pair Corr
0.42	DNA	Ginkgo Bioworks Holdings	Pair Corr
0.39	DYAI	Dyadic International	Pair Corr

The ability to find closely correlated positions to Altamira Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altamira Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altamira Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altamira Therapeutics to buy it.

The correlation of Altamira Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altamira Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altamira Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Altamira Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Altamira Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Altamira Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Altamira Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Altamira Therapeutics Stock:

How To Invest In Altamira

Details

Is Altamira Stock a good investment?

Details

What is Altamira Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.82

Revenue Per Share

0.917

Quarterly Revenue Growth

(0.64)

Return On Assets

(0.57)

Return On Equity

(3.69)

The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Altamira End Period Cash Flow vs Begin Period Cash Flow Analysis

End Period Cash Flow vs Begin Period Cash Flow

End Period Cash Flow vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Begin Period Cash Flow

Altamira Therapeutics fundamental ratios Correlations

Altamira Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Altamira Therapeutics fundamental ratios Accounts

Pair Trading with Altamira Therapeutics

Moving together with Altamira Stock

Moving against Altamira Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Intangible Assets	+ 0.99	Non Current Assets Total
Total Current Assets	+ 0.98	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Total Current Assets	- 0.96	Net Debt
Common Stock Shares Outstanding	- 0.95	Short Term Investments
Net Debt	- 0.95	Total Stockholder Equity